Solid Biosciences (SLDB) Total Current Liabilities (2017 - 2026)

Solid Biosciences has reported Total Current Liabilities for 10 years, with the latest figure at $30.3 million in Q1 2026.

• Quarterly Total Current Liabilities rose 5.23% year-over-year to $30.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $30.3 million (up 5.23% YoY) and the FY2025 annual result came in at $33.5 million, up 10.63% from the prior year.
• Total Current Liabilities eased to $30.3 million in Q1 2026 per SLDB's latest filing, from $33.5 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $36.3 million in Q3 2025 and troughed at $14.3 million in Q1 2024.
• A 5-year average of $23.0 million and a median of $21.7 million in 2022 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2023 and 2024: Total Current Liabilities slumped 35.5% in 2023, then jumped 108.42% in 2024.
• Over 5 years, Total Current Liabilities stood at $22.5 million in 2022, then plunged by 35.5% to $14.5 million in 2023, then surged by 108.42% to $30.3 million in 2024, then grew by 10.63% to $33.5 million in 2025, then slipped by 9.53% to $30.3 million in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $30.3 million, $33.5 million, and $36.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.